Intellectual Product
WuXi AppTec Faces Uncertainty Amid BIOSECURE Act, Yet Continues to Secure New Projects
BIOSECURE Act, WuXi AppTec, Biotechnology Industry, U.S. Legislation, Contract Development and Manufacturing Organizations (CDMOs), Biopharma Outsourcing, National Security Concerns
Mitigating Risks in mRNA Manufacturing: Strategies for Smooth Transition from Preclinical to Clinical Stages
mRNA manufacturing, risk management, preclinical to clinical transition, quality control, regulatory compliance, raw material selection, process automation, analytical methods.
Fierce Pharma AsiaAstellas’ first-in-class FDA nod; Otsuka’s IgAN win; Samsung Bio’s $1.2B contract
United States Food and Drug Administration, IGA Glomerulonephritis, Sibeprenlimab, Contract agreement, Samsung, first
Alpha-9 Radios Secures $175M Funding for RLT Portfolio Advancement
Alpha-9 radios, $175M funding, RLT portfolio, radiopharmaceuticals, biotech investment
Samsung Biologics Secures $1.2 Billion Production Contract, Boosting 2024 Deal Value to Over $3.3 Billion
Samsung Biologics, CDMO, Contract Manufacturing, Biopharmaceuticals, Production Contract, 2024 Deal Value
Takeda Terminates Partnership with Wave Life Sciences on Huntington’s Disease Program
Takeda, Wave Life Sciences, Huntington’s disease, WVE-003, partnership termination, biotech news
AI-Driven Recognition of Disease Signatures in Cellular Pathway Visualizations
Artificial Intelligence (AI), Neural Networks, Disease Signatures, Cellular Pathway Visualizations, Transcriptomic Analysis, Machine Learning
CMS Unveils Preliminary List of 101 Generic Drugs for Medicare $2 Out-of-Pocket Plan
Medicare $2 Drug List Model, generic drugs, out-of-pocket costs, medication adherence, health outcomes, CMS Innovation Center
Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges
Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination
Novo Nordisk and Viatris Settle Patent Dispute Over Ozempic and Wegovy, Keeping Generic Entry Date Undisclosed
Novo Nordisk, Viatris, Mylan Pharmaceuticals, Ozempic, Wegovy, Patent Dispute, Generic Entry Date, Settlement Agreement